GIPC1 and breast cancer: Therefore, the GIPC1 signature may be capable of distinguishing patient outcome within groups of high-grade breast cancers, particularly those that are ER+, and not simply distinguishing tumor grade (high vs. low) or ER status (positive versus negative).